One To Watch

Fusion Pharmaceuticals

Company Overview

A Canadian clinical-stage biopharmaceutical company developing next-generation targeted radioconjugates for oncology, acquired by AstraZeneca in 2024 for approximately $2 billion to accelerate the radiopharmaceutical pipeline. Fusion's platform combines tumor-targeting vectors with alpha-particle-emitting isotopes to deliver localized, high-energy radiation directly to cancer cells. The company was built on the premise that targeted alpha therapy could replace or supplement conventional chemotherapy and external radiotherapy regimens.

Headquarters and Global Presence

Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada, with research operations linked to McMaster University's nuclear medicine infrastructure. Following the AstraZeneca acquisition, Fusion's programs operate within AstraZeneca's Oncology R&D unit alongside a broader radiopharmaceutical strategy.

Founding and History

Fusion was founded in Canada and completed a $25 million Series A financing at its launch, signaling early institutional confidence in its targeted alpha therapy approach. The company grew into a clinical-stage organization with multiple programs advancing through Phase I and Phase II trials. In March 2024, AstraZeneca announced a definitive agreement to acquire Fusion for approximately $2 billion, describing the deal as a pivotal step in its ambition to transform cancer treatment. The acquisition positioned AstraZeneca to compete directly with Novartis and Eli Lilly in the rapidly expanding radiopharmaceutical space.

Therapy Areas and Focus

Fusion's pipeline is focused entirely on oncology, targeting solid tumors with high unmet medical need where conventional treatment options are inadequate. The company has pursued indications including prostate cancer, gastrointestinal stromal tumors, and other solid tumor types driven by well-validated molecular targets. Its rationale rests on the ability of alpha-emitting isotopes to deliver dense, short-range ionizing radiation that limits off-target toxicity compared to beta-emitters. This precision is seen as especially relevant in tumors with heterogeneous antigen expression.

Technology Platforms and Modalities

Fusion's core technology is its radioconjugate platform, which links targeting ligands — including antibodies and small molecules — to actinium-225, an alpha-particle-emitting radioisotope. Alpha particles deliver approximately 100-fold greater linear energy transfer than beta particles, enabling potent cytotoxicity within a range of just a few cell diameters. The platform is designed to minimize systemic radiation exposure while maximizing tumor kill, addressing a key limitation of earlier radiopharmaceutical approaches. Fusion's proprietary isotope supply chain and linker chemistry were cited as competitive differentiators at the time of the AstraZeneca acquisition.

Key Pipeline and Programs

FPI-2265 is Fusion's most advanced asset, an actinium-225-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC). It entered Phase II development as an actinium-labeled PSMA radioconjugate, directly competing in the PSMA-targeted space pioneered by Novartis's lutetium-177-based Pluvicto but using an alpha emitter for potentially greater potency. FPI-1434 is an actinium-225-labeled antibody targeting insulin-like growth factor 1 receptor (IGF-1R), advancing in Phase I trials across multiple solid tumor types. FPI-2059 targets neurotensin receptor 1 (NTSR1), a receptor overexpressed in several gastrointestinal and other solid tumors, and was in Phase I evaluation. The breadth of targets across PSMA, IGF-1R, and NTSR1 reflects Fusion's strategy of validating its actinium-225 platform across multiple oncology indications before the AstraZeneca deal closed.

Recent Developments

In March 2024, AstraZeneca announced a definitive agreement to acquire Fusion Pharmaceuticals for approximately $2 billion, with the deal framed as a cornerstone of AstraZeneca's push into next-generation radiopharmaceuticals. The acquisition was completed in mid-2024, integrating Fusion's radioconjugate pipeline into AstraZeneca's global Oncology R&D infrastructure. AstraZeneca described the deal as enabling it to replace traditional chemotherapy and radiotherapy regimens for patients with hard-to-treat solid tumors. The transaction reflected the broader sector-wide surge in radiopharmaceutical investment, with deals also occurring at Eli Lilly, Bristol Myers Squibb, and Lantheus during the same period.

Key Personnel

John Valliant serves as Chief Executive Officer and is the scientific founder of Fusion, with deep expertise in radiochemistry and nuclear medicine developed at McMaster University. Eric Burak serves as Chief Technology Officer, overseeing the radioconjugate manufacturing platform and isotope supply chain. John Crowley serves as Chief Financial Officer, having guided the company's financing strategy from early Series A funding through to the $2 billion AstraZeneca transaction.

Strategic Partnerships

The defining strategic event for Fusion is its acquisition by AstraZeneca for approximately $2 billion, announced in March 2024 and completed the same year. AstraZeneca positioned the deal explicitly as a means to build out a next-generation radioconjugate franchise capable of challenging Novartis's established radiopharmaceutical business. Prior to the acquisition, Fusion had raised institutional venture financing, including its founding Series A of $25 million, to advance its platform through clinical proof-of-concept.

FAQ Section

AstraZeneca acquired Fusion in 2024 to rapidly establish a competitive position in targeted radioconjugates, a modality where Novartis had already gained approval for Pluvicto in prostate cancer. Fusion brought a clinical-stage pipeline anchored by actinium-225-based assets, a differentiated alpha-emitting isotope platform, and proprietary supply chain infrastructure that would have taken years to replicate internally. The deal was part of a broader industry wave of radiopharmaceutical acquisitions, including moves by Eli Lilly, Bristol Myers Squibb, and others during 2023-2024.

Actinium-225 is an alpha-particle emitter delivering approximately 100-fold higher linear energy transfer than lutetium-177, a beta emitter used in approved agents like Pluvicto. This means actinium-225 can kill cancer cells with fewer decays, operating over a much shorter tissue range of just a few cell diameters, which theoretically reduces collateral damage to surrounding healthy tissue. The greater potency of alpha particles is also expected to be effective in tumors with lower or heterogeneous antigen expression, where beta-emitter-based therapies may underperform.

Where antibody-drug conjugates (ADCs) deliver cytotoxic small molecules to tumor cells, Fusion's radioconjugates replace the drug payload with an actinium-225 radioisotope, enabling radiation to be deposited directly at the tumor site. The alpha particles emitted cause double-strand DNA breaks that are difficult for cancer cells to repair, a mechanism distinct from the chemical cytotoxicity of ADC payloads. Fusion's platform also uses small molecule targeting vectors alongside antibodies, allowing access to tumor-cell-surface receptors that may be less amenable to antibody-based delivery.

FPI-2265 is an actinium-225-labeled PSMA-targeting radioconjugate in development for metastatic castration-resistant prostate cancer, the same indication addressed by Novartis's lutetium-177 PSMA agent Pluvicto. The asset progressed into Phase II clinical evaluation, making it Fusion's most clinically advanced program at the time of the AstraZeneca acquisition. Its differentiation rests on the alpha-emitting isotope, which may deliver greater tumor kill than Pluvicto's beta-emitting lutetium-177, particularly in patients with lower PSMA expression.

Fusion extended its radioconjugate platform beyond prostate cancer through FPI-1434, targeting IGF-1R across multiple solid tumor types in Phase I, and FPI-2059, targeting neurotensin receptor 1 (NTSR1) expressed in gastrointestinal and other solid tumors, also in Phase I. This multi-indication strategy was designed to demonstrate the versatility of the actinium-225 platform across different tumor biology and targeting vectors. Under AstraZeneca, these programs are expected to be prioritized alongside AstraZeneca's existing oncology portfolio for potential combination approaches.

At the time of the March 2024 acquisition announcement, Fusion was a clinical-stage company with its lead asset FPI-2265 in Phase II and two additional programs, FPI-1434 and FPI-2059, in Phase I trials. The company had advanced from a $25 million Series A at founding to a multi-program clinical organization, representing significant de-risking of the actinium-225 platform. Integration into AstraZeneca's infrastructure is expected to accelerate enrollment, expand manufacturing scale, and enable combinations with AstraZeneca's portfolio of targeted oncology agents.

Fusion's pipeline now sits within one of the industry's most ambitious radiopharmaceutical buildouts, but several watchpoints remain critical for investors and observers tracking the AstraZeneca oncology franchise:

Want to Update your Company's Profile?